Roivant Sciences

Yahoo Finance • 7 days ago

Monday 9/22 Insider Buying Report: HAIN, ROIV

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th... Full story

Yahoo Finance • 12 days ago

Stocks Settle Mixed on Hawkish Fed Chair Powell Comments

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Wednesday closed down -0.10%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.... Full story

Yahoo Finance • 12 days ago

Stocks Tread Water as FOMC Decision Nears

The S&P 500 Index ($SPX) (SPY) today is down -0.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.62%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.42%.  September E-mini S&P futures (ESU25) are down -0.09%, and September E-... Full story

Yahoo Finance • 12 days ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, including measurements of skin disease, muscl... Full story

Yahoo Finance • 15 days ago

Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock

Vivek Ramaswamy sold more than $22 million worth of Roivant Sciences stock in three separate transactions last week, according to a filing with the U.S. Securities and Exchange Commission. Ramaswamy founded Roivant Sciences in 2014 and ser... Full story

Yahoo Finance • 18 days ago

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

BASEL, Switzerland and LONDON and NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have selected Roivant (Nasdaq: ROIV) for the 2025 Fortune Best Workplaces in BioPharma™ List. This is Roivant’s firs... Full story

Yahoo Finance • 18 days ago

Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat

In this article, we will be taking a look at the 7 Hot Healthcare Stocks to Buy Right Now. Roivant Sciences Ltd. is one of them. Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company focused on accelerating the... Full story

Yahoo Finance • 25 days ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including priority review and extended market exclusivity for potential treatments targeting diseases for which there is no suffi... Full story

Yahoo Finance • 26 days ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3... Full story

Yahoo Finance • 2 months ago

Roivant plans $500M new share repurchase as brepocitinib data readout nears

Earnings Call Insights: Roivant Sciences Ltd. (ROIV) Q1 2025 MANAGEMENT VIEW * CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," highlighting three main themes: progress with IMVT-1402 and... Full story

Yahoo Finance • 2 months ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business update. Brepocitinib VALOR Phas... Full story

Yahoo Finance • 2 months ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial... Full story

Yahoo Finance • 3 months ago

Immunovant (IMVT) chief technology officer Stout sells $26k in stock

Immunovant, Inc. (NASDAQ:IMVT) Chief Technology Officer Jay S. Stout, sold 1,519 shares of common stock on July 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average p... Full story

Yahoo Finance • 3 months ago

Goldman Sachs resumes Immunovant stock coverage with Neutral rating

Investing.com - Goldman Sachs resumed coverage of Immunovant (NASDAQ:IMVT) with a Neutral rating and set an $18.00 price target, close to InvestingPro’s Fair Value calculation. The company, currently valued at nearly $3 billion, trades wit... Full story

Yahoo Finance • 3 months ago

Goldman Sachs resumes Roivant Sciences stock coverage with Buy rating

Investing.com - Goldman Sachs has resumed coverage of Roivant Sciences (NASDAQ:ROIV) with a Buy rating and a price target of $19.00, according to a research note released Thursday. The target represents a significant upside from the curren... Full story

Yahoo Finance • 3 months ago

ROIV Makes Notable Cross Below Critical Moving Average

In trading on Tuesday, shares of Roivant Sciences Ltd (Symbol: ROIV) crossed below their 200 day moving average of $11.22, changing hands as low as $11.05 per share. Roivant Sciences Ltd shares are currently trading down about 1.7% on the... Full story

Yahoo Finance • 3 months ago

Roivant Sciences sets $500M stock repurchase program

* Roivant Sciences (NASDAQ:ROIV [https://seekingalpha.com/symbol/ROIV]) has set a stock repurchase program to buy back up to $500M of its common shares. * The program will be funded with available cash and cash equivalents on hand and... Full story

Yahoo Finance • 3 months ago

Roivant Sciences authorizes $500 million share repurchase program

Roivant Sciences Ltd. (NASDAQ:ROIV) announced Tuesday that its board of directors has authorized a new common share repurchase program of up to $500 million. The program allows the company to buy back its common shares using available cash... Full story

Yahoo Finance • 3 months ago

Roivant Sciences' president Venker sells $1.15 million in shares

Eric Venker, President and COO of Roivant Sciences (NASDAQ:ROIV), sold 100,000 common shares of the company on June 20, 2025, for $11.45 each, totaling $1.15 million. The transaction occurred near the stock’s current trading price of $11.5... Full story

Yahoo Finance • 3 months ago

Roivant Sciences (ROIV): Ramaswamy sells $13 million in shares

Vivek Ramaswamy, a ten percent owner of Roivant Sciences Ltd (NASDAQ:ROIV), sold a total of 1,142,273 common shares in two separate transactions, according to a Form 4 filing with the Securities and Exchange Commission. The sales amounted... Full story